Author: GlobeNewswire

The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been…

PALO ALTO, Calif., March 25, 2022 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc.…

International Conference on Alzheimer’s and Parkinson’s Diseases Provides New Insights into the Role of Neuroinflammation in AD and the Promise…

Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large…

Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line…

CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared…

Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment…

Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with…

COPENHAGEN, Denmark, March 24, 2022 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative…

FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a…